Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

globenewswire

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints – NEWSnet – News… as it used to be

More Press Releases

May 3, 2026

Radaris People Search Sites in 2026 Complete Guide to Finding Someone Online today

May 3, 2026

A New Vision for Smart Parenting Unveiled at Toys & Children, Baby and Maternity Products Category of 139th Canton Fair

May 3, 2026

A Decade of Learning Across Borders: PKU’s South-South Institute Turns 10

May 3, 2026

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

Radaris People Search Sites in 2026 Complete Guide to Finding Someone Online today

A New Vision for Smart Parenting Unveiled at Toys & Children, Baby and Maternity Products Category of 139th Canton Fair

A Decade of Learning Across Borders: PKU’s South-South Institute Turns 10

139th Canton Fair Phase 3 Advances Toward a Better Life with New and Strengthened Product Zones